Vpx rescues HIV-1 transduction of dendritic cells from the antiviral state established by type 1 interferon

Retrovirology

Volumn 8, Issue , 2011, Pages

  Pertel, Thomas ^a   Reinhard, Christian ^a   Luban, Jeremy ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; COMPLEMENTARY DNA; GENE PRODUCT; INTERFERON; LIPOPOLYSACCHARIDE; MESSENGER RNA; PATTERN RECOGNITION RECEPTOR; POLY(DEOXYADENYLATE DEOXYTHYMIDYLATE); POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN DCAF1; PROTEIN VPX; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; VPX PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 2; VPX PROTEIN, SIMIAN IMMUNODEFICIENCY VIRUS;

ARTICLE; CELL DIFFERENTIATION; CELL NUCLEUS; CONTROLLED STUDY; DENDRITIC CELL; GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; INTERFERON PRODUCTION; INTERFERON STIMULATED GENE; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION; SIMIAN IMMUNODEFICIENCY VIRUS; TARGET CELL; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS LIKE AGENT; VIRUS TRANSCRIPTION; CELL CULTURE; GENETIC TRANSDUCTION; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; METABOLISM; VIROLOGY;

CERCOCEBUS TORQUATUS ATYS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; LENTIVIRUS; MACACA MULATTA; VESICULAR STOMATITIS VIRUS;

CELLS, CULTURED; DENDRITIC CELLS; HIV-1; HUMANS; INTERFERON TYPE I; TRANSDUCTION, GENETIC; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 79959353247     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-8-49     Document Type: Article

References (93)

1. Malim MH, Emerman M. HIV-1 accessory proteins--ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3:388-398. 10.1016/j.chom.2008.04.008, 18541215.
2. Tristem M, Marshall C, Karpas A, Hill F. Evolution of the primate lentiviruses: evidence from vpx and vpr. EMBO J 1992, 11:3405-3412. 556875, 1324171.
3. Sharp PM, Bailes E, Stevenson M, Emerman M, Hahn BH. Gene acquisition in HIV and SIV. Nature 1996, 383:586-587. 10.1038/383586a0, 8857532.
4. Gibbs JS, Lackner AA, Lang SM, Simon MA, Sehgal PK, Daniel MD, Desrosiers RC. Progression to AIDS in the absence of a gene for vpr or vpx. J Virol 1995, 69:2378-2383. 188910, 7884883.
5. Hirsch VM, Sharkey ME, Brown CR, Brichacek B, Goldstein S, Wakefield J, Byrum R, Elkins WR, Hahn BH, Lifson JD, Stevenson M. Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: evidence of macrophage-dependent viral amplification. Nat Med 1998, 4:1401-1408. 10.1038/3992, 9846578.
6. Yu XF, Yu QC, Essex M, Lee TH. The vpx gene of simian immunodeficiency virus facilitates efficient viral replication in fresh lymphocytes and macrophage. J Virol 1991, 65:5088-5091. 248975, 1714525.
7. Balliet JW, Kolson DL, Eiger G, Kim FM, McGann KA, Srinivasan A, Collman R. Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology 1994, 200:623-631. 10.1006/viro.1994.1225, 8178448.
8. Gibbs JS, Regier DA, Desrosiers RC. Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses 1994, 10:607-616. 10.1089/aid.1994.10.607, 7917522.
9. Kawamura M, Sakai H, Adachi A. Human immunodeficiency virus Vpx is required for the early phase of replication in peripheral blood mononuclear cells. Microbiol Immunol 1994, 38:871-878.
10. Goujon C, Riviere L, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cimarelli A. SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology 2007, 4:2. 10.1186/1742-4690-4-2, 1779362, 17212817.
11. Goujon C, Arfi V, Pertel T, Luban J, Lienard J, Rigal D, Darlix JL, Cimarelli A. Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells. J Virol 2008, 82:12335-12345. 10.1128/JVI.01181-08, 2593360, 18829761.
12. Sharova N, Wu Y, Zhu X, Stranska R, Kaushik R, Sharkey M, Stevenson M. Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog 2008, 4:e1000057. 10.1371/journal.ppat.1000057, 2323106, 18451984.
13. Srivastava S, Swanson SK, Manel N, Florens L, Washburn MP, Skowronski J. Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection. PLoS Pathog 2008, 4:e1000059. 10.1371/journal.ppat.1000059, 2330158, 18464893.
14. Fujita M, Otsuka M, Miyoshi M, Khamsri B, Nomaguchi M, Adachi A. Vpx is critical for reverse transcription of the human immunodeficiency virus type 2 genome in macrophages. J Virol 2008, 82:7752-7756. 10.1128/JVI.01003-07, 2493314, 18495778.
15. Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, Descamps D, Damond F, Brun-Vezinet F, Nisole S, et al. The HIV-2 Vpx protein usurps the CUL4A-DDB1DCAF1 ubiquitin ligase to overcome a post-entry block in macrophage infection. J Virol 2009,
16. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. Journal of virology 2000, 74:6087-6095. 10.1128/JVI.74.13.6087-6095.2000, 112107, 10846092.
17. Sewell AK, Price DA. Dendritic cells and transmission of HIV-1. Trends in immunology 2001, 22:173-175. 10.1016/S1471-4906(01)01866-X, 11274909.
18. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464:217-223. 10.1038/nature08757, 20220840.
19. Accola MA, Bukovsky AA, Jones MS, Gottlinger HG. A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm). J Virol 1999, 73:9992-9999. 113050, 10559313.
20. Paxton W, Connor RI, Landau NR. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol 1993, 67:7229-7237. 238185, 8230445.
21. Wu X, Conway JA, Kim J, Kappes JC. Localization of the Vpx packaging signal within the C terminus of the human immunodeficiency virus type 2 Gag precursor protein. J Virol 1994, 68:6161-6169. 237035, 8083957.
22. Jenkins Y, Pornillos O, Rich RL, Myszka DG, Sundquist WI, Malim MH. Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag). Journal of virology 2001, 75:10537-10542. 10.1128/JVI.75.21.10537-10542.2001, 114634, 11581428.
23. Belshan M, Mahnke LA, Ratner L. Conserved amino acids of the human immunodeficiency virus type 2 Vpx nuclear localization signal are critical for nuclear targeting of the viral preintegration complex in non-dividing cells. Virology 2006, 346:118-126. 10.1016/j.virol.2005.10.036, 16325220.
24. Di Marzio P, Choe S, Ebright M, Knoblauch R, Landau NR. Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. J Virol 1995, 69:7909-7916. 189735, 7494303.
25. Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, Gendelman HE, Ratner L, Stevenson M, Emerman M. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994, 91:7311-7315. 10.1073/pnas.91.15.7311, 44389, 8041786.
26. Fletcher TM, Brichacek B, Sharova N, Newman MA, Stivahtis G, Sharp PM, Emerman M, Hahn BH, Stevenson M. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J 1996, 15:6155-6165. 452436, 8947037.
27. Freed EO, Englund G, Martin MA. Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. Journal of virology 1995, 69:3949-3954. 189124, 7745752.
28. Yamashita M, Emerman M. The cell cycle independence of HIV infections is not determined by known karyophilic viral elements. PLoS pathogens 2005, 1:e18. 10.1371/journal.ppat.0010018, 1283251, 16292356.
29. Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cimarelli A. With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). Gene Ther 2006, 13:991-994. 10.1038/sj.gt.3302753, 16525481.
30. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003, 9:1398-1403. 10.1038/nm946, 14528301.
31. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003, 9:1404-1407. 10.1038/nm945, 14528300.
32. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302:1056-1060. 10.1126/science.1089591, 14564014.
33. Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, Cohen EA. HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog 2007, 3:e85. 10.1371/journal.ppat.0030085, 1914068, 17630831.
34. Hrecka K, Gierszewska M, Srivastava S, Kozaczkiewicz L, Swanson SK, Florens L, Washburn MP, Skowronski J. Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci USA 2007, 104:11778-11783. 10.1073/pnas.0702102104, 1906728, 17609381.
35. Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, Transy C, Margottin-Goguet F. HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 2007, 6:182-188. 10.4161/cc.6.2.3732, 17314515.
36. Schrofelbauer B, Hakata Y, Landau NR. HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc Natl Acad Sci USA 2007, 104:4130-4135. 10.1073/pnas.0610167104, 1820720, 17360488.
37. Tan L, Ehrlich E, Yu XF. DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J Virol 2007, 81:10822-10830. 10.1128/JVI.01380-07, 2045451, 17626091.
38. Luban J. Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J Virol 2007, 81:1054-1061. 10.1128/JVI.01519-06, 1797489, 16956947.
39. Pertel T, Hausmann S, Morger D, Züger S, Guerra J, Lascano J, Reinhard C, Santoni F, Uchil PD, Chatel L, et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 2011, 472:361-365. 10.1038/nature09976, 21512573.
40. Kornbluth RS, Oh PS, Munis JR, Cleveland PH, Richman DD. Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. J Exp Med 1989, 169:1137-1151. 10.1084/jem.169.3.1137, 2189273, 2466937.
41. Panne D, Maniatis T, Harrison SC. An atomic model of the interferon-beta enhanceosome. Cell 2007, 129:1111-1123. 10.1016/j.cell.2007.05.019, 2020837, 17574024.
42. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826. 10.1038/nature06246, 17943118.
43. Pancio HA, Ratner L. Human immunodeficiency virus type 2 Vpx-Gag interaction. J Virol 1998, 72:5271-5275. 110118, 9573303.
44. Selig L, Pages JC, Tanchou V, Preveral S, Berlioz-Torrent C, Liu LX, Erdtmann L, Darlix J, Benarous R, Benichou S. Interaction with the p6 domain of the gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses. J Virol 1999, 73:592-600. 103865, 9847364.
45. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206:935-944. 10.1006/viro.1995.1016, 7531918.
46. Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, Kallis S, Zayas M, Lohmann V, Luban J, Bartenschlager R. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog 2009, 5:e1000546. 10.1371/journal.ppat.1000546, 2718831, 19680534.
47. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). International journal of cancer 1980, 26:171-176.
48. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005, 437:1167-1172. 10.1038/nature04193, 16177806.
49. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M, Lemon SM. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005, 102:2992-2997. 10.1073/pnas.0408824102, 548795, 15710891.
50. Lin R, Lacoste J, Nakhaei P, Sun Q, Yang L, Paz S, Wilkinson P, Julkunen I, Vitour D, Meurs E, Hiscott J. Dissociation of a MAVS/IPS-1/VISA/Cardif-IKKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage. J Virol 2006, 80:6072-6083. 10.1128/JVI.02495-05, 1472616, 16731946.
51. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, Wang T, Ishida H, Yoneyama M, et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA 2006, 103:6001-6006. 10.1073/pnas.0601523103, 1458687, 16585524.
52. Drahos J, Racaniello VR. Cleavage of IPS-1 in cells infected with human rhinovirus. Journal of virology 2009, 83:11581-11587. 10.1128/JVI.01490-09, 2772720, 19740998.
53. Barral PM, Sarkar D, Fisher PB, Racaniello VR. RIG-I is cleaved during picornavirus infection. Virology 2009, 391:171-176. 10.1016/j.virol.2009.06.045, 2743091, 19628239.
54. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS pathogens 2009, 5:e1000574. 10.1371/journal.ppat.1000574, 2729927, 19730691.
55. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS pathogens 2009, 5:e1000450. 10.1371/journal.ppat.1000450, 2679223, 19478868.
56. Douglas JL, Viswanathan K, McCarroll MN, Gustin JK, Fruh K, Moses AV. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. Journal of virology 2009, 83:7931-7947. 10.1128/JVI.00242-09, 2715753, 19515779.
57. Goila-Gaur R, Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 2008, 5:51. 10.1186/1742-4690-5-51, 2443170, 18577210.
58. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, Bieniasz PD. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009, 139:499-511. 10.1016/j.cell.2009.08.039, 2844890, 19879838.
59. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650. 10.1038/nature00939, 12167863.
60. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430. 10.1038/nature06553, 18200009.
61. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3:245-252. 10.1016/j.chom.2008.03.001, 2474773, 18342597.
62. McNab FW, Rajsbaum R, Stoye JP, O'Garra A. Tripartite-motif proteins and innate immune regulation. Current opinion in immunology 2011, 23:46-56. 10.1016/j.coi.2010.10.021, 21131187.
63. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog 2008, 4:e16. 10.1371/journal.ppat.0040016, 2222954, 18248090.
64. Kajaste-Rudnitski A, Marelli SS, Pultrone C, Pertel T, Uchil PD, Mechti N, Mothes W, Poli G, Luban J, Vicenzi E. TRIM22 Inhibits HIV-1 Transcription Independently of Its E3-Ubiquitin Ligase Activity, Tat and NF-{kappa}B Responsive LTR Elements. Journal of virology 2011,
65. Bogerd HP, Wiegand HL, Hulme AE, Garcia-Perez JL, O'Shea KS, Moran JV, Cullen BR. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci USA 2006, 103:8780-8785. 10.1073/pnas.0603313103, 1482655, 16728505.
66. Chen H, Lilley CE, Yu Q, Lee DV, Chou J, Narvaiza I, Landau NR, Weitzman MD. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 2006, 16:480-485. 10.1016/j.cub.2006.01.031, 16527742.
67. Berger A, Munk C, Schweizer M, Cichutek K, Schule S, Flory E. Interaction of Vpx and apolipoprotein B mRNA-editing catalytic polypeptide 3 family member A (APOBEC3A) correlates with efficient lentivirus infection of monocytes. The Journal of biological chemistry 2010, 285:12248-12254. 10.1074/jbc.M109.090977, 2852964, 20178977.
68. Peng G, Greenwell-Wild T, Nares S, Jin W, Lei KJ, Rangel ZG, Munson PJ, Wahl SM. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 2007, 110:393-400. 10.1182/blood-2006-10-051763, 1896122, 17371941.
69. Hrecka K, Hao1 C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011,
70. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011,
71. DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, Planelles V. HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 2007, 4:57. 10.1186/1743-422X-4-57, 1904188, 17559673.
72. Wen X, Duus KM, Friedrich TD, de Noronha CM. The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor. J Biol Chem 2007, 282:27046-27057. 10.1074/jbc.M703955200, 17620334.
73. Yamashita M, Emerman M. Retroviral infection of non-dividing cells: old and new perspectives. Virology 2006, 344:88-93. 10.1016/j.virol.2005.09.012, 16364740.
74. Yamashita M, Perez O, Hope TJ, Emerman M. Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells. PLoS pathogens 2007, 3:1502-1510. 2042020, 17967060.
75. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 2010, 467:214-217. 10.1038/nature09337, 3051279, 20829794.
76. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998, 392:245-252. 10.1038/32588, 9521319.
77. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426. 10.1038/nature06175, 17898760.
78. Medzhitov R, Littman D. HIV immunology needs a new direction. Nature 2008, 455:591. 10.1038/455591a, 18833256.
79. Negre D, Mangeot PE, Duisit G, Blanchard S, Vidalain PO, Leissner P, Winter AJ, Rabourdin-Combe C, Mehtali M, Moullier P, et al. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther 2000, 7:1613-1623. 10.1038/sj.gt.3301292, 11083469.
80. Papkalla A, Munch J, Otto C, Kirchhoff F. Nef enhances human immunodeficiency virus type 1 infectivity and replication independently of viral coreceptor tropism. J Virol 2002, 76:8455-8459. 10.1128/JVI.76.16.8455-8459.2002, 155138, 12134048.
81. Schindler M, Munch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, Muller-Trutwin MC, Novembre FJ, Peeters M, Courgnaud V, et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006, 125:1055-1067. 10.1016/j.cell.2006.04.033, 16777597.
82. He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, Busciglio J, Yang X, Hofmann W, Newman W, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997, 385:645-649. 10.1038/385645a0, 9024664.
83. Chen BK, Saksela K, Andino R, Baltimore D. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J Virol 1994, 68:654-660. 236499, 7507183.
84. Berthoux L, Sebastian S, Sokolskaja E, Luban J. Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J Virol 2004, 78:11739-11750. 10.1128/JVI.78.21.11739-11750.2004, 523245, 15479815.
85. Zhang YJ, Hatziioannou T, Zang T, Braaten D, Luban J, Goff SP, Bieniasz PD. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol 2002, 76:6332-6343. 10.1128/JVI.76.12.6332-6343.2002, 136233, 12021366.
86. Mangeot PE, Duperrier K, Negre D, Boson B, Rigal D, Cosset FL, Darlix JL. High levels of transduction of human dendritic cells with optimized SIV vectors. Mol Ther 2002, 5:283-290. 10.1006/mthe.2002.0541, 11863418.
87. Pizzato M, Erlwein O, Bonsall D, Kaye S, Muir D, McClure MO. A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants. J Virol Methods 2009, 156:1-7. 10.1016/j.jviromet.2008.10.012, 19022294.
88. Simm M, Shahabuddin M, Chao W, Allan JS, Volsky DJ. Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol 1995, 69:4582-4586. 189210, 7769728.
89. Kappes JC, Parkin JS, Conway JA, Kim J, Brouillette CG, Shaw GM, Hahn BH. Intracellular transport and virion incorporation of vpx requires interaction with other virus type-specific components. Virology 1993, 193:222-233. 10.1006/viro.1993.1118, 8438567.
90. Uze G, Di Marco S, Mouchel-Vielh E, Monneron D, Bandu MT, Horisberger MA, Dorques A, Lutfalla G, Mogensen KE. Domains of interaction between alpha interferon and its receptor components. J Mol Biol 1994, 243:245-257. 10.1006/jmbi.1994.1651, 7932753.
91. Butler SL, Hansen MS, Bushman FD. A quantitative assay for HIV DNA integration in vivo. Nat Med 2001, 7:631-634. 10.1038/87979, 11329067.
92. Braaten D, Franke EK, Luban J. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol 1996, 70:3551-3560. 190230, 8648689.
93. Zhang J, Scadden DT, Crumpacker CS. Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest 2007, 117:473-481. 10.1172/JCI28971, 1783820, 17273559.